Pulmonary Fibrosis Biomarkers Market, By Type of Biomarkers (Diagnostic Biomarkers, Prognostic Biomarkers, and Predictive Biomarkers), By Application, By End-user, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
REPORT HIGHLIGHT
Pulmonary Fibrosis Biomarkers Market size was valued at US$ 4,290.43 Million in 2024, expanding at a CAGR of 4.50% from 2025 to 2032.
Pulmonary fibrosis biomarkers are crucial biological indicators that aid in diagnosing, monitoring, and predicting the progression of pulmonary fibrosis, a chronic lung disease characterized by excessive scarring of lung tissue. These biomarkers, which include proteins, genes, and other molecular signals found in blood, urine, or tissue samples, help clinicians assess disease activity and treatment responses. Commonly studied biomarkers such as KL-6, SP-D, and CCL18 are used to track lung inflammation and fibrosis severity, providing valuable insights for disease management. Research into pulmonary fibrosis biomarkers plays a vital role in early detection, personalized medicine, and the development of novel therapies. Since pulmonary fibrosis often shares symptoms with other lung diseases, biomarkers improve diagnostic accuracy and help differentiate it from conditions like chronic obstructive pulmonary disease (COPD) or asthma. As ongoing studies continue to identify new biomarkers, their integration into clinical practice is expected to enhance treatment strategies, improve patient outcomes, and support drug development efforts for this complex disease.
Pulmonary Fibrosis Biomarkers Market- Market Dynamics
Ø Rising incidence of pulmonary fibrosis drives demand for biomarkers in diagnosis.
The rising incidence of pulmonary fibrosis (PF) is a major factor fueling the growth of the biomarkers market. In countries like India, the prevalence of idiopathic pulmonary fibrosis (IPF) is estimated to range between 14 to 43 per 100,000 people, highlighting an urgent need for early and accurate diagnostic tools. Studies indicate that IPF accounts for approximately 17% of all interstitial lung diseases (ILDs) in the country, underscoring the importance of timely detection and intervention. Additionally, cities like Pune have reported a 5-7% annual increase in IPF cases, further amplifying the demand for advanced diagnostic solutions. As pulmonary fibrosis cases continue to rise worldwide, the need for reliable biomarkers to diagnose the disease, monitor its progression, and evaluate treatment responses is more critical than ever. Biomarkers such as KL-6, SP-D, and CCL18 offer significant potential in improving disease management and guiding personalized treatment approaches. This growing demand is driving research and innovation, leading to the development of more precise and effective diagnostic tools for pulmonary fibrosis.
Pulmonary Fibrosis Biomarkers Market- Segmentation Analysis:
The Global Pulmonary Fibrosis Biomarkers Market is segmented on the basis of Type of Biomarkers, Application, End-user, and Region.
The market is divided into three categories based on Type of Biomarkers: Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers. The Diagnostic Biomarkers segment is the most dominant and significant in the Pulmonary Fibrosis Biomarkers market. Early and precise detection of pulmonary fibrosis (PF) is essential for improving patient outcomes, and diagnostic biomarkers play a key role in this process. These biomarkers help identify PF in its initial stages, allowing for timely intervention to slow disease progression. Given that conditions like idiopathic pulmonary fibrosis (IPF) share symptoms with other lung diseases, diagnostic biomarkers are critical in distinguishing PF from similar disorders, leading to faster and more accurate diagnoses. Biomarkers such as KL-6, SP-D, and CCL18 are increasingly utilized in clinical settings to aid in diagnosing IPF and other forms of pulmonary fibrosis. The rising awareness of PF and its growing prevalence, particularly in regions like the U.S., is further driving demand for reliable diagnostic tools. This need is fueling ongoing research and development efforts to introduce more advanced and effective biomarkers, ensuring the continued dominance of the diagnostic biomarkers segment in the market.
The market is divided into three categories based on application: Diagnosis, Treatment Monitoring, Drug Development. The diagnosis segment is the most critical in the Pulmonary Fibrosis Biomarkers market, as early and accurate detection is essential for improving patient outcomes and facilitating timely treatment. Pulmonary fibrosis (PF), particularly idiopathic pulmonary fibrosis (IPF), often presents symptoms similar to other lung diseases, leading to frequent misdiagnoses. This makes diagnostic biomarkers indispensable for differentiating PF from similar conditions. Biomarkers such as KL-6, SP-D, and CCL18 are widely used in clinical practice due to their effectiveness in detecting PF at early stages when intervention can significantly slow disease progression. With the increasing prevalence of PF, the demand for reliable diagnostic tools continues to grow, driving research into new and more advanced biomarkers. Additionally, as healthcare providers and research institutions prioritize early detection, the diagnostic application remains central to market growth and ongoing innovation in pulmonary fibrosis biomarkers.
Pulmonary Fibrosis Biomarkers Market- Geographical Insights
North America is a key player in the Pulmonary Fibrosis Biomarkers market, driven by its advanced healthcare infrastructure, high prevalence of pulmonary diseases, and strong research initiatives. The United States holds a substantial market share, supported by leading research institutions, pharmaceutical companies, and a growing number of clinical trials. With approximately 200,000 individuals diagnosed with idiopathic pulmonary fibrosis (IPF) in the U.S., there is a significant demand for diagnostic biomarkers to facilitate early detection and disease management. Additionally, government organizations like the National Institutes of Health (NIH) are actively funding research to identify and validate biomarkers, fostering innovation. The region’s well-established healthcare reimbursement systems further support the adoption of emerging biomarker technologies in clinical settings. Increasing awareness of pulmonary fibrosis and advancements in personalized medicine are also driving market expansion. The United States plays a dominant role in the Pulmonary Fibrosis Biomarkers market due to its cutting-edge healthcare system and strong investment in medical research. With over 200,000 diagnosed cases of IPF, the need for reliable biomarkers for early detection, prognosis, and treatment monitoring continues to grow. Government funding, particularly through the NIH, is accelerating the discovery and development of new biomarkers, advancing diagnostic tools and therapeutic solutions. Additionally, the U.S. pharmaceutical industry actively collaborates with research institutions to enhance biomarker-driven innovations, further strengthening the country’s leadership in the market.
Pulmonary Fibrosis Biomarkers Market- Competitive Landscape:
The Pulmonary Fibrosis Biomarkers market features a competitive landscape comprising both leading pharmaceutical companies and specialized biotech firms. Industry giants such as Genentech, F. Hoffmann-La Roche, and Gilead Sciences dominate the market, leveraging their strong research capabilities and extensive portfolios in pulmonary diseases. These companies focus on advancing biomarker discovery, conducting clinical trials, and integrating biomarkers into treatment strategies. Meanwhile, emerging biotech firms like Biodesix and Thermo Fisher Scientific are making notable advancements with innovative biomarker platforms and diagnostic tools specifically designed for pulmonary fibrosis. The market is also shaped by strategic collaborations between pharmaceutical companies and research institutions, aimed at accelerating biomarker validation and commercialization. As personalized medicine gains traction, competition continues to intensify, with companies striving to develop more precise and effective diagnostic and therapeutic solutions.
Recent Developments:
v In October 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for BMS-986278, a first-in-class oral lysophosphatidic acid receptor 1 (LPA1) antagonist, for the treatment of progressive pulmonary fibrosis (PPF). This designation underscores the drug’s potential in addressing this severe and life-threatening disease while strengthening the company’s product portfolio.
v In March 2020, Bristol Myers Squibb partnered with the Pulmonary Fibrosis Foundation (PFF) to identify biomarkers, aiming to accelerate the development of targeted therapies for pulmonary fibrosis. This collaboration reinforced the company’s commitment to improving patient outcomes while supporting advancements in precision medicine. Additionally, the initiative contributed to increased sales and revenue growth.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Ø Biodesix, Inc.
Ø Genentech, Inc.
Ø F. Hoffmann-La Roche Ltd.
Ø Bristol-Myers Squibb Company
Ø AbbVie Inc.
Ø Thermo Fisher Scientific Inc.
Ø Abbott Laboratories
Ø PerkinElmer, Inc.
Ø Eli Lilly and Company
Ø Gilead Sciences, Inc.
Ø Novartis International AG
Ø Johnson & Johnson
Ø Mylan N.V.
Ø Sanofi S.A.
Ø Amgen Inc.
GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY TYPE OF BIOMARKERS- MARKET ANALYSIS, 2019 - 2032
Ø Diagnostic Biomarkers
Ø Prognostic Biomarkers
Ø Predictive Biomarkers
GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032
Ø Diagnosis
Ø Treatment Monitoring
Ø Drug Development
GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032
Ø Hospitals & Clinics
Ø Diagnostic Laboratories
Ø Research & Academic Institutions
GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
Ø North America
o U.S.
o Canada
Ø Europe
o Germany
o UK
o France
o Italy
o Spain
o The Netherlands
o Sweden
o Russia
o Poland
o Rest of Europe
Ø Asia Pacific
o China
o India
o Japan
o South Korea
o Australia
o Indonesia
o Thailand
o Philippines
o Rest of APAC
Ø Latin America
o Brazil
o Mexico
o Argentina
o Colombia
o Rest of LATAM
Ø The Middle East and Africa
o Saudi Arabia
o UAE
o Israel
o Turkey
o Algeria
o Egypt
o Rest of MEA
TABLE OF CONTENT
1. Pulmonary Fibrosis Biomarkers Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Pulmonary Fibrosis Biomarkers Market Snippet by Type of Biomarkers
2.1.2. Pulmonary Fibrosis Biomarkers Market Snippet by Application
2.1.3. Pulmonary Fibrosis Biomarkers Market Snippet by End-user
2.1.4. Pulmonary Fibrosis Biomarkers Market Snippet by Country
2.1.5. Pulmonary Fibrosis Biomarkers Market Snippet by Region
2.2. Competitive Insights
3. Pulmonary Fibrosis Biomarkers Key Market Trends
3.1. Pulmonary Fibrosis Biomarkers Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Pulmonary Fibrosis Biomarkers Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Pulmonary Fibrosis Biomarkers Market Opportunities
3.4. Pulmonary Fibrosis Biomarkers Market Future Trends
4. Pulmonary Fibrosis Biomarkers Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Pulmonary Fibrosis Biomarkers Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Pulmonary Fibrosis Biomarkers Market Landscape
6.1. Pulmonary Fibrosis Biomarkers Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Pulmonary Fibrosis Biomarkers Market – By Type of Biomarkers
7.1. Overview
7.1.1. Segment Share Analysis, By Type of Biomarkers, 2024 & 2032 (%)
7.1.2. Diagnostic Biomarkers
7.1.3. Prognostic Biomarkers
7.1.4. Predictive Biomarkers
8. Pulmonary Fibrosis Biomarkers Market – By Application
8.1. Overview
8.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
8.1.2. Diagnosis
8.1.3. Treatment Monitoring
8.1.4. Drug Development
9. Pulmonary Fibrosis Biomarkers Market – By End-user
9.1. Overview
9.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
9.1.2. Hospitals & Clinics
9.1.3. Diagnostic Laboratories
9.1.4. Research & Academic Institutions
10. Pulmonary Fibrosis Biomarkers Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
10.2.1. Overview
10.2.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.2.4. North America Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.8. UK
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.8.3. UK Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.3.8.4. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.3.8.5. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.9. France
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.9.3. France Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.3.9.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.3.9.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.10. Italy
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.10.3. Italy Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.3.10.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.3.10.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.11. Spain
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.11.3. Spain Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.3.11.4. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.3.11.5. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.12. The Netherlands
10.3.12.1. Overview
10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.12.3. The Netherlands Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.3.12.4. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.3.12.5. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.13. Sweden
10.3.13.1. Overview
10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.3.13.5. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.14. Russia
10.3.14.1. Overview
10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.14.3. Russia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.3.14.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.3.14.5. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.15. Poland
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.15.3. Poland Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.3.15.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.3.15.5. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3.16. Rest of Europe
10.3.16.1. Overview
10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.16.3. Rest of the Europe Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.3.16.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Asia Pacific
10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.4.4. APAC Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.4.5. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.4.6. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.7. China
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.7.3. China Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.4.7.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.4.7.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.8. India
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.8.3. India Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.4.8.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.4.8.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.12. Indonesia
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.12.3. Indonesia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.4.12.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.4.12.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.13. Thailand
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.13.3. Thailand Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.4.13.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.4.13.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
10.5.1. Overview
10.5.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Latin America
10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.5.4. LATAM Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.5.5. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.5.6. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
10.6.1. Overview
10.6.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Middle East and Africa
10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.6.4. MEA Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.6.5. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.6.6. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6.8. UAE
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.8.3. UAE Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.6.8.4. UAE Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.6.8.5. UAE Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11. Key Vendor Analysis- Pulmonary Fibrosis Biomarkers Industry
11.1. Competitive Dashboard
11.1.1. Competitive Benchmarking
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. Biodesix, Inc.
11.2.2. Genentech, Inc.
11.2.3. F. Hoffmann-La Roche Ltd.
11.2.4. Bristol-Myers Squibb Company
11.2.5. AbbVie Inc.
11.2.6. Thermo Fisher Scientific Inc.
11.2.7. Abbott Laboratories
11.2.8. PerkinElmer, Inc.
11.2.9. Eli Lilly and Company
11.2.10. Gilead Sciences, Inc.
11.2.11. Novartis International AG
11.2.12. Johnson & Johnson
11.2.13. Mylan N.V.
11.2.14. Sanofi S.A.
11.2.15. Amgen Inc.
12. 360 Degree AnalystView
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
